Q1 Earnings Forecast for NeuroPace Issued By Leerink Partnrs

NeuroPace, Inc. (NASDAQ:NPCE) – Leerink Partnrs issued their Q1 2025 earnings per share estimates for NeuroPace in a research report issued to clients and investors on Thursday, April 3rd. Leerink Partnrs analyst M. Kratky anticipates that the company will post earnings of ($0.24) per share for the quarter. The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share. Leerink Partnrs also issued estimates for NeuroPace’s Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.51) EPS, FY2027 earnings at ($0.26) EPS, FY2028 earnings at $0.20 EPS and FY2029 earnings at $0.59 EPS.

Several other equities analysts have also weighed in on the company. Cantor Fitzgerald increased their price objective on NeuroPace from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. UBS Group initiated coverage on NeuroPace in a research note on Tuesday, January 21st. They set a “buy” rating and a $17.00 price target for the company. Wells Fargo & Company boosted their price objective on NeuroPace from $13.00 to $17.00 and gave the company an “overweight” rating in a research note on Thursday, January 30th. Finally, JPMorgan Chase & Co. upped their price objective on shares of NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, NeuroPace currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.20.

NeuroPace Stock Up 0.6 %

NeuroPace stock opened at $12.30 on Monday. The firm has a 50 day moving average price of $12.52 and a 200-day moving average price of $10.49. The company has a quick ratio of 4.77, a current ratio of 5.59 and a debt-to-equity ratio of 6.03. NeuroPace has a twelve month low of $5.45 and a twelve month high of $15.77. The company has a market capitalization of $400.49 million, a P/E ratio of -12.30 and a beta of 2.03.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The company had revenue of $21.47 million for the quarter, compared to the consensus estimate of $21.14 million.

Insider Transactions at NeuroPace

In other news, major shareholder Ltd. Kck sold 5,270,845 shares of the business’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $9.40, for a total transaction of $49,545,943.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Martha Morrell sold 78,334 shares of the company’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $13.72, for a total transaction of $1,074,742.48. Following the completion of the transaction, the insider now directly owns 81,993 shares in the company, valued at approximately $1,124,943.96. The trade was a 48.86 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,352,479 shares of company stock valued at $50,670,217 over the last three months. Company insiders own 22.20% of the company’s stock.

Institutional Investors Weigh In On NeuroPace

Several large investors have recently added to or reduced their stakes in NPCE. BNP Paribas Financial Markets purchased a new stake in shares of NeuroPace in the 4th quarter valued at about $29,000. GAMMA Investing LLC purchased a new stake in NeuroPace in the first quarter valued at approximately $53,000. Wells Fargo & Company MN raised its stake in NeuroPace by 54.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,483 shares of the company’s stock valued at $73,000 after purchasing an additional 2,279 shares in the last quarter. MetLife Investment Management LLC bought a new stake in NeuroPace during the fourth quarter valued at approximately $103,000. Finally, Cubist Systematic Strategies LLC purchased a new position in NeuroPace in the 4th quarter worth approximately $112,000. Institutional investors own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.